Navigation Links
Translating Preclinical Pharmacology to Clinical Activity with Myriad RBM’s Inflammation MAP
Date:4/22/2013

Toronto, Canada (PRWEB) April 22, 2013

Pre-clinical assessment of a novel investigational product should include an evaluation of the compounds’ pharmacokinetic/pharmacodynamic (PK/PD) profile. This information, combined with toxicology studies, is crucial for deciding dosage regimens. New approaches, such as Minimal Anticipated Biological Effect Level (MABEL), can inform go/no-go decisions for additional clinical research.

In this webinar, a case study using the immunotherapeutic small molecule VTX-2337, will help to show how this preclinical evaluation can be done effectively. VTX-2337 is a potent and selective small molecule (<500 MW) TLR8 agonist that activates myeloid dendritic cells, monocytes and NK cells to produce both chemokines and Th1 polarizing cytokines, including TNFa, IL-12 and IFN?.

The presenter, Dr. Gregory Dietsch, Vice President of Research at VentiRx Pharmaceuticals, will discuss translating preclinical pharmacology to clinical activity with Myriad RBM’s Inflammation MAP.

To join the webinar and engage in an online discussion about preclinical pharmacology and VTX-2337, visit: http://xtks.in/xto594wp

Xtalks, powered by Honeycomb Worldwide Inc., is a leading provider of educational webinars to the global Life Sciences community. Every year, thousands of industry practitioners turn to Xtalks for access to quality content. Xtalks helps Life Science professionals stay current with industry developments, trends and regulations. Xtalks webinars also provide perspectives on key issues from top industry thought leaders and service providers.

To learn more about Xtalks, visit http://xtalks.com/ContactUs.ashx.

Contact:
Karen Lim (416) 977-6555 ext 227
clientservices(at)xtalks(dot)com

Read the full story at http://www.prweb.com/releases/2013/4/prweb10652881.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related biology technology :

1. PROLOR Biotech To Present New Preclinical Data On Its Long-Acting Clotting Factor VIIa At Leading European Scientific Conference
2. RPCI-Led Study: FAK Inhibitor Proves Effective Against Brain Tumors in Preclinical Studies
3. Stemline Therapeutics, Inc. Announces Presentations of SL-401 Updated Clinical Trial Results in Acute Myeloid Leukemia (AML) and Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) and SL-101 Preclinical Efficacy Data Against Hodgkins Lymphoma at
4. Inovio Pharmaceuticals Cytomegalovirus (CMV) Synthetic Vaccine Constructs Generate Strong and Broad T-Cell Responses in Preclinical Study
5. Karyopharm Therapeutics Announces Oral Presentation at the American College of Rheumatology (ACR) on the use of Selective Inhibitors of Nuclear Export (SINE) CRM1 Antagonists in preclinical models of Systemic Lupus Erythematosus (SLE)
6. Preclinical data shows 100 percent prevention and treatment of influenza with engineered human antibody
7. Karyopharm Therapeutics announces the Publication of Two Preclinical Studies on the Activity of Selective Inhibitors of Nuclear Export (SINE) in Acute Myeloblastic Leukemia (AML)
8. MultiCell Technologies Announces Positive Preclinical Results for MCT-465 and MCT-485 in Primary Liver Cancer In Vitro Models
9. AtheroNova Inc. Preclinical Study Demonstrates 95% Reduction in Arterial Plaque Formation
10. ChemoCentryx Presents Positive Results for Novel CCR2 Inhibitor in Preclinical Models of Diabetic Nephropathy at the 44th Annual Meeting of the American Society of Nephrology
11. A “Fail Fast” Strategy for Lead Optimization Pharmacology and Toxicology, New Xtalks Life Sciences Webinar
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/19/2017)... ... January 18, 2017 , ... The American Medical Informatics Association ... Data Sharing Policy. Specifically, the nation’s leading informatics experts, said data sharing plans ... policy. AMIA recommended that NIH earmark funding for researchers to produce and execute ...
(Date:1/19/2017)... Island, NY (PRWEB) , ... January 19, 2017 , ... ... at an exponential rate. The tremendous growth is accounted to two main factors. ... the table and the expanding network of vendors supplying FireflySci products all around the ...
(Date:1/19/2017)... YORK , Jan. 18, 2017 ... to reach USD 92.9 billion by 2025, according ... Inc. Pharmaceutical industry has been adaptive of the ... as early as 2002. Among the services outsourced, ... forerunners. For instance, Johnson & Johnson was the ...
(Date:1/19/2017)... PLAINVIEW, N.Y. , Jan. 18, 2017 ... pathology services, announces the formation of an Executive Committee ... 2017 and beyond. John Cucci , ... been promoted from Director of Business Development to ... in 2015, Mr. Cucci served in senior sales leadership ...
Breaking Biology Technology:
(Date:12/12/2016)... 12, 2016  Researchers at Trinity College, Dublin, ... by combining the material with Silly Putty. The mixture ... detector able to sense pulse, blood pressure, respiration, ... The research team,s findings were ... here:  http://science.sciencemag.org/content/354/6317/1257 ...
(Date:12/8/2016)... 2016  Singulex, Inc., the leader in Next Generation ... a license and supply agreement with Thermo Fisher Scientific, ... Singulex access to Thermo Scientific BRAHMS PCT (Procalcitonin), a ... used to diagnose systemic bacterial infection and sepsis and ... aid in assessing the risk of critically ill patients ...
(Date:12/7/2016)... TEL AVIV, Israel , December 7, 2016 ... year with the expansion of its patent portfolio, which grew to over ... , , ... led by its recently filed patent entitled " System, Device, ... which covers technology that enables device makers to forego costly hardware components ...
Breaking Biology News(10 mins):